Psychiatrienet - User contributions [en]

Tranylcypromine-vortioxetine

2026-04-14T15:02:38Z

Casper:

{{Drugswitch
| from = tranylcypromine
| to = vortioxetine
| stop =
{{stopTranyl}}
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>
| start =
* A wash-out period of two weeks is necessary.
* '''Day 23:''' start administration of vortioxetine in a normal dosage of 10 mg/day. <ref name="informatorium">{{KNMP|tranylcypromine}}</ref>

| caveat =
* Occurrence of the serotonin syndrome is possible without a wash-out period.
| info =
{{Tcrestore}}
}}

Fenelzine-vortioxetine

2026-04-14T15:02:17Z

Casper:

{{Drugswitch
| from = fenelzine
| to = vortioxetine
| stop =
{{stopFenel}}
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>
| start =
* A wash-out period of two weeks is necessary.
* '''Day 23:''' start administration of vortioxetine in a normal dosage of 10 mg/day. <ref name="informatorium">{{KNMP|fenel}}</ref>

| caveat =
* Occurrence of the serotonin syndrome is possible without a wash-out period.
| info =
{{Tcrestore}}
}}

Fenelzine-vortioxetine

2026-04-14T14:59:26Z

Casper:

{{Drugswitch
| from = fenelzine
| to = vortioxetine
| stop =
{{stopFenel}}
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>
| start =
* A wash-out period of two weeks is necessary.
* '''Day 28:''' start administration of vortioxetine in a normal dosage of 10 mg/day. <ref name="informatorium">{{KNMP|fenel}}</ref>

| caveat =
* Occurrence of the serotonin syndrome is possible without a wash-out period.
| info =
{{Tcrestore}}
}}

Fenelzine-vortioxetine

2026-04-14T14:59:00Z

Casper:

{{Drugswitch
| from = fenelzine
| to = vortioxetine
| stop =
{{stopFenel}}
| start =
* A wash-out period of two weeks is necessary.
* '''Day 28:''' start administration of vortioxetine in a normal dosage of 10 mg/day. <ref name="informatorium">{{KNMP|fenel}}</ref>

| caveat =
* Occurrence of the serotonin syndrome is possible without a wash-out period.
| info =
{{Tcrestore}}
}}

Fenelzine-vortioxetine

2026-04-14T14:58:31Z

Casper:

{{Drugswitch
| from = fenelzine
| to = vortioxetine
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>
| stop =
{{stopFenel}}
| start =
* A wash-out period of two weeks is necessary.
* '''Day 28:''' start administration of vortioxetine in a normal dosage of 10 mg/day. <ref name="informatorium">{{KNMP|fenel}}</ref>

| caveat =
* Occurrence of the serotonin syndrome is possible without a wash-out period.
| info =
{{Tcrestore}}
}}

Tranylcypromine-fenelzine

2026-04-14T14:56:12Z

Casper:

{{Drugswitch
| from = tranylcypromine
| to = fenelzine
| stop =
*Decrease tranylcypromine with 10 mg every 2 weeks.
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>

| start =
*A washout period of 14 days is necessary
{{Startfenel}}
| caveat =
{{caveSS}}
{{switchMAO}}

}}

Fenelzine-tranylcypromine

2026-04-14T14:56:02Z

Casper:

{{Drugswitch
| from = fenelzine
| to = tranylcypromine
| stop =
*Decrease fenelzine with 15 mg every 2 weeks.
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>

| start =
*A washout period of 14 days is necessary
{{Starttranyl}}
| caveat =
{{caveSS}}
{{switchMAO}}

}}

Fenelzine-tranylcypromine

2026-04-14T14:55:43Z

Casper:

{{Drugswitch
| from = fenelzine
| to = tranylcypromine
| stop =
*Decrease fenelzine with 15 mg every 2 weeks.
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>

| start =
A washout period of 14 days is necessary
{{Starttranyl}}
| caveat =
{{caveSS}}
{{switchMAO}}

}}

Fenelzine-tranylcypromine

2026-04-14T14:55:25Z

Casper:

{{Drugswitch
| from = fenelzine
| to = tranylcypromine
| stop =
A washout period of 14 days is necessary
*Decrease fenelzine with 15 mg every 2 weeks.
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref>

| start =
{{Starttranyl}}
| caveat =
{{caveSS}}
{{switchMAO}}

}}

Fenelzine-nortriptyline

2026-04-14T14:52:38Z

Casper:

{{Drugswitch
| from = fenelzine
| to = nortriptyline
| stop =
{{stopFenel}}
| start =
{{Inc25p3d15}} <ref name="informatorium">{{KNMP|fenelzine}}</ref>
| info =
{{Tcrestore}}
* Fenelzine has to be phased out to avoid withdrawal symptoms.<ref>Dr. M.J.Blom et al. (2009) Gebruik van klassieke MAO-remmers</ref>
{{TCAplasmalevelmonitoring}}

}}

Fenelzine-mirtazapine

2026-04-14T14:49:54Z

Casper:

{{Drugswitch
| from = fenelzine
| to = mirtazapine
| stop =
{{stopFenel}}
| start =
{{Inc25p3do50pw}} <ref name="informatorium">{{KNMP|fenelzine}}</ref>
| info =
{{Tcrestore}}
*Safe target dose mirtazapine is 15mg.
}}

Fenelzine-fluoxetine

2026-04-14T14:43:34Z

Casper:

{{Drugswitch
| from = fenelzine
| to = fluoxetine
| stop =
{{stopFenel}}
| start =
* '''Day 23 and after''': start fluoxetine at 100% of the target dose.<ref name="informatorium">{{KNMP|fenelzine}}</ref>
* ''' After 3 weeks:''' If necessary, gradually increase dosage of fluoxetine.
| info =
{{Tcwashout}}
{{Tcrestore}}<ref name="informatorium">{{KNMP|fenelzine}}</ref>
* Fenelzine has to be phased out to avoid withdrawal symptoms.<ref>Dr. M.J.Blom et al. (2009) Gebruik van klassieke MAO-remmers</ref>

}}

Fenelzine-citalopram

2026-04-14T14:42:04Z

Casper:

{{Drugswitch
| from = fenelzine
| to = citalopram
| stop =
{{stopFenel}}
| start =
{{28Inc50pw}} <ref name="informatorium">{{KNMP|fenelzine}}</ref>
| info =
{{Tcrestore}}
{{Tcwashout}}

}}

Venlafaxine-paroxetine

2026-04-14T14:22:00Z

Casper:

{{Drugswitch
| from = venlafaxine
| to = paroxetine
| stop =
{{TCAdecrease25p3d}}
| start =
* '''Day 7 and after''': At approximately 50-25% of the original venlafaxine dose start paroxetine at 50% of the target dose.
* '''Day 14:''' Increase paroxetine to 100% of the target dose

| info =
* Safe target dose paroxetine = 20 mg
* Paroxetine is an inhibitor of CYP2D6 (strong), which metabolizes venlafaxine. It prolongs the halftime of venlafaxine which decreases the chances of withdrawal
}}

Tranylcypromine-fluoxetine

2026-04-14T14:09:28Z

Casper:

{{Drugswitch
| from = tranylcypromine
| to = fluoxetine
| stop =
{{stopTranyl}}
| start =
* '''Day 23 and after''': start fluoxetine at 100% of the target dose.<ref name="informatorium">{{KNMP|tranylcypromine}}</ref>
* ''' After 3 weeks:''' If necessary, gradually increase dosage of fluoxetine.
| info =
{{Tcwashout}}
{{Tcrestore}}<ref name="informatorium">{{KNMP|tranylcypromine}}</ref>
* Tranylcypromine has to be phased out to avoid withdrawal symptoms.<ref>Dr. M.J.Blom et al. (2009) Gebruik van klassieke MAO-remmers</ref>

}}

Paroxetine-trazodone

2026-04-14T14:00:01Z

Casper:

{{Drugswitch
| from = paroxetine
| to = trazodone
| stop = {{StopSSRI,SNRI}}
| start =
* '''Day 1:''' {{startTrazo}}
* ''' Day 8:''' {{upTrazo}}
| info =
* If trazodon is to be used in a dosage below 100mg it will not have serotonin inhibiting effects. In that case gradually reduce your paroxetine dosage and do '''NOT''' use this switch
}}

Imipramine-fluoxetine

2026-04-14T13:20:30Z

Casper:

{{Drugswitch
| from = imipramine
| to = fluoxetine
| stop =
{{TCAdecrease25p3d}}
| start =
* '''Day 6 and after''': At approximately 50-25% of the original TCA dose start fluoxetine at 100% of the target dose.
* ''' After 3 weeks:''' If necessary, gradually increase dosage of fluoxetine.

| info =
* Safe target dose fluoxetine = 20 mg
* Fluoxetine and norfluoxetine are inhibitors of CYP2D6 (strong), which metabolize desipramine (a metabolite of imipramine).
}}

Fluoxetine-venlafaxine

2026-04-14T13:11:10Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = venlafaxine
| stop =
{{stopfluox}}
| start =
Caution is necessary for at least four weeks.
* '''Day 5:''' start administration of venlafaxine in a low dosage of 37,5 mg/day.
* '''Day 15:''' increase dosage of venlafaxine to 75 mg/day.
* '''Day 20 and after:''' increase dosage of venlafaxine if necessary.
| info =
* Fluoxetine and norfluoxetine slow the metabolism of venlafaxine via CYP2D6.
* Tapering fluoxetine to 20mg before stopping is not necessary, because of strong serotonergic activity of target drug.
{{longt1/2fluvox}}
}}

Fluoxetine-venlafaxine

2026-04-14T13:09:48Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = venlafaxine
| stop =
{{stopfluox}}
| start =
* '''Day 5:''' start administration of venlafaxine in a low dosage of 37,5 mg/day.
* '''Day 15:''' increase dosage of venlafaxine to 75 mg/day.
* '''Day 20 and after:''' increase dosage of venlafaxine if necessary.
| info =
* Fluoxetine and norfluoxetine slow the metabolism of venlafaxine via CYP2D6.
* Tapering fluoxetine to 20mg before stopping is not necessary, because of strong serotonergic activity of target drug.
{{longt1/2fluvox}}
}}

Fluoxetine-clomipramine

2026-04-14T11:29:56Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = clomipramine
| stop = {{stopfluox}}
| start =
Caution is necessary for at least four weeks.
* '''Day 5:''' start administration of clomipramine in a low dosage of 37.5 mg/day.
* '''Day 15:''' increase dosage of clomipramine to 75 mg/day.
* '''Day 20 and after:''' gradually increase dosage of clomipramine if necessary.
| info =
* {{TCAplasmalevelmonitoring}}
* Tapering fluoxetine to 20mg before stopping is not necessary, because of strong serotonergic activity of target drug.
{{longt1/2fluvox}}
* Fluoxetine and norfluoxetine slow the metabolism of clomipramine via CYP2D6.
* Start low, go slow for clomipramine.
}}

Fluoxetine-maprotiline

2026-04-14T11:20:20Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = maprotiline
| stop =
{{stopFluoxetine1}}
| start =
Caution is necessary for at least four weeks.
* '''Day 5:''' start administration of maprotiline in a low dosage of 25 mg/day.
* '''Day 15:''' increase dosage of maprotiline to 50 mg/day.
* '''Day 20 and after:''' gradually increase dosage of maprotiline if necessary.
| info =
* {{TCAplasmalevelmonitoring}}
* Fluoxetine and norfluoxetine slow the metabolism of maprotiline via CYP2D6.
{{longt1/2fluvox}}
* Start low, go slow for maprotiline.}}

Fluoxetine-imipramine

2026-04-14T11:13:30Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = imipramine
| stop =
{{stopfluox}}
| start =
Caution is necessary for at least four weeks.
* '''Day 5:''' start administration of imipramine in a low dosage of 25 mg/day.
* '''Day 15:''' increase dosage of imipramine to 50 mg/day.
* '''Day 20 and after:''' gradually increase dosage of imipramine if necessary.
| info =
* {{TCAplasmalevelmonitoring}}
* Tapering fluoxetine to 20mg before stopping is not necessary, because of strong serotonergic activity of target drug.
{{longt1/2fluvox}}
* Fluoxetine and norfluoxetine slow the metabolism of imipramine via CYP2D6.
* Start low, go slow for imipramine.
}}

Fluoxetine-clomipramine

2026-04-14T11:10:45Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = clomipramine
| stop = {{stopfluox}}
| start =
Caution is necessary for at least four weeks.
* '''Day 5:''' start administration of clomipramine in a low dosage of 37.5 mg/day.
* '''Day 15:''' increase dosage of clomipramine to 75 mg/day.
* '''Day 20 and after:''' gradually increase dosage of clomipramine if necessary.
| info =
* {{TCAplasmalevelmonitoring}}
* Tapering fluoxetine to 20mg before stopping is not necessary, because of strong serotonergic activity of target drug.
* Fluoxetine and norfluoxetine slow the metabolism of clomipramine via CYP2D6.
{{longt1/2fluvox}}
* Start low, go slow for clomipramine.
}}

Fluoxetine-clomipramine

2026-04-14T11:08:29Z

Casper:

{{Drugswitch
| from = fluoxetine
| to = clomipramine
| stop = {{stopfluox}}
| start =
* '''Day 5:''' start administration of clomipramine in a low dosage of 37.5 mg/day.
* '''Day 15:''' increase dosage of clomipramine to 75 mg/day.
* '''Day 20 and after:''' gradually increase dosage of clomipramine if necessary.
| info =
* {{TCAplasmalevelmonitoring}}
* Tapering fluoxetine to 20mg before stopping is not necessary, because of strong serotonergic activity of target drug.
* Fluoxetine and norfluoxetine slow the metabolism of clomipramine via CYP2D6.
{{longt1/2fluvox}}
* Start low, go slow for clomipramine.
}}

Project:Updates Switch Tables

2026-01-28T10:36:44Z

Casper:

=== Updates Switch Tables ===
===== January 2026 =====
*Antipsychotics: Reviewed and updated switches from Partial Agonist (PA) to other antipsychotics except PA - Clozapine. Change: stop PA on day 1 instead of phasing out.

===== March 2024 =====
* Antidepressants: Reviewed and updated switches to tranylcypromine, fluoxetine and moclobemide (not finished)
* Updated e-mail: medisch@boom.nl

===== August 2023 =====
* Antidepressants: Reviewed and updated switches from and to agomelatine, moclobemide and bupropion (not finished).

===== June 2023 =====
* Antidepressants: Reviewed and updated switches from TCA to SSRI and SSRI to TCA (not finished)

===== February 2023 =====
* Antidepressants: Reviewed and updated switches from SSRI to SSRI and SSRI to SNRI (not finished)
* Changed reference of literature in switch table

===== March 2022 =====
* Antipsychotics: Certain long acting to long acting switches deleted.
* Antipsychotics: oral to different antipsychotic long acting deleted.
* Antipsychotics: added penfluridol
* Antipsychotics: added paliperidone extended release formulations (Xeplion, Trivecta, Byannli)
* Antipsychotics: ziprasidone moved to rest AP
* Antipsychotics: paliperidone moved from rest AP
* Introduced Updates Switch Tables page for informing users about changes on the Switchwiki

===== October 2021 =====
* Antipsychotics: added group partial antagonists

If you any have suggestions, please send them to info@tijdstroom.nl. We are looking forward to your feedback.

Project:Updates Switch Tables

2026-01-28T10:07:37Z

Casper:

=== Updates Switch Tables ===
===== January 2026 =====
*Antipsychotics: Reviewed and updated all switches from Partial Agonist (PA) to other antipsychotics. Change: stop PA on day 1 instead of phasing out.

===== March 2024 =====
* Antidepressants: Reviewed and updated switches to tranylcypromine, fluoxetine and moclobemide (not finished)
* Updated e-mail: medisch@boom.nl

===== August 2023 =====
* Antidepressants: Reviewed and updated switches from and to agomelatine, moclobemide and bupropion (not finished).

===== June 2023 =====
* Antidepressants: Reviewed and updated switches from TCA to SSRI and SSRI to TCA (not finished)

===== February 2023 =====
* Antidepressants: Reviewed and updated switches from SSRI to SSRI and SSRI to SNRI (not finished)
* Changed reference of literature in switch table

===== March 2022 =====
* Antipsychotics: Certain long acting to long acting switches deleted.
* Antipsychotics: oral to different antipsychotic long acting deleted.
* Antipsychotics: added penfluridol
* Antipsychotics: added paliperidone extended release formulations (Xeplion, Trivecta, Byannli)
* Antipsychotics: ziprasidone moved to rest AP
* Antipsychotics: paliperidone moved from rest AP
* Introduced Updates Switch Tables page for informing users about changes on the Switchwiki

===== October 2021 =====
* Antipsychotics: added group partial antagonists

If you any have suggestions, please send them to info@tijdstroom.nl. We are looking forward to your feedback.

Project:Updates Switch Tables

2026-01-28T10:06:40Z

Casper:

=== Updates Switch Tables ===
===== January 2026 =====
*Antipsychotics: Reviewed and updated all switches from Partial Agonist (PA).

===== March 2024 =====
* Antidepressants: Reviewed and updated switches to tranylcypromine, fluoxetine and moclobemide (not finished)
* Updated e-mail: medisch@boom.nl

===== August 2023 =====
* Antidepressants: Reviewed and updated switches from and to agomelatine, moclobemide and bupropion (not finished).

===== June 2023 =====
* Antidepressants: Reviewed and updated switches from TCA to SSRI and SSRI to TCA (not finished)

===== February 2023 =====
* Antidepressants: Reviewed and updated switches from SSRI to SSRI and SSRI to SNRI (not finished)
* Changed reference of literature in switch table

===== March 2022 =====
* Antipsychotics: Certain long acting to long acting switches deleted.
* Antipsychotics: oral to different antipsychotic long acting deleted.
* Antipsychotics: added penfluridol
* Antipsychotics: added paliperidone extended release formulations (Xeplion, Trivecta, Byannli)
* Antipsychotics: ziprasidone moved to rest AP
* Antipsychotics: paliperidone moved from rest AP
* Introduced Updates Switch Tables page for informing users about changes on the Switchwiki

===== October 2021 =====
* Antipsychotics: added group partial antagonists

If you any have suggestions, please send them to info@tijdstroom.nl. We are looking forward to your feedback.

Sertraline-fluvoxamine

2025-02-20T15:10:06Z

Casper:

{{Drugswitch
| from = sertraline
| to = fluvoxamine
| stop =
{{TCAdecrease25p3d}}
| start =
{{StartfluvoxIA}}
| info =
* Fluvoxamine is an inhibitor of CYP2C19, which metabolize sertraline.
* Safe target dose fluvoxamine = 100mg
}}

Sertraline-fluvoxamine

2025-02-20T15:09:41Z

Casper:

Dosulepine-fluvoxamine

2025-02-20T14:50:46Z

Casper:

{{Drugswitch
| from = dosulepine
| to = fluvoxamine
| stop =
{{TCAdecrease25p3d}}
| start =
{{StartfluvoxIA}}
| info =
* Fluvoxamine is an inhibitor of CYP2C19, which metabolize dosulepine.
* Safe target dose fluvoxamine = 100 mg
}}

Clomipramine-fluvoxamine

2025-02-20T14:06:17Z

Casper:

{{Drugswitch
| from = clomipramine
| to = fluvoxamine
| stop =
{{TCAdecrease25p3d}}
| start =
{{StartfluvoxIA}}
| info =
* Fluvoxamine is an inhibitor of CYP2C19, which metabolize clomipramine.
* Safe target dose fluvoxamine = 100 mg
}}

Citalopram-fluvoxamine

2025-02-20T14:05:53Z

Casper:

{{Drugswitch
| from = citalopram
| to = fluvoxamine
| stop =
{{TCAdecrease25p3d}}
| start =
{{StartfluvoxIA}}
| info =
* Fluvoxamine is an inhibitor of CYP2C19, which metabolize citalopram.
* Safe target dose fluvoxamine = 100 mg
}}

Amitriptyline-fluvoxamine

2025-02-20T14:00:09Z

Casper:

{{Drugswitch
| from = amitriptyline
| to = fluvoxamine
| stop =
{{TCAdecrease25p3d}}
| start =
{{StartfluvoxIA}}
| info =
* Fluvoxamine is an inhibitor of CYP2C19, which metabolize amitriptyline.
* Safe target dose fluvoxamine = 100 mg
}}

Template:SPCaripiprazoleLA

2025-02-20T11:33:38Z

Casper:

* More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. <ref>https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena SPC of the European Medicines Agency on aripiprazole depot</ref>
* Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 300mg and 400mg (once a month) and 720mg and 960mg (once every two months).

Template:SPCaripiprazoleLA

2025-02-20T11:29:24Z

Casper:

* More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. <ref>https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena SPC of the European Medicines Agency on aripiprazole depot</ref>
* Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 400mg (once a month) and 960mg (once every two months) preparations. A reduced dose of 75% (300mg and 720mg respectively) can be needed when experiencing side effects.

Template:SPCaripiprazoleLA

2025-02-20T11:22:10Z

Casper:

* More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. <ref>https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena SPC of the European Medicines Agency on aripiprazole depot</ref>
* Aripiprazol Abilify Maintena is a prolonged release suspension for injection and is available in 400mg and 960mg preparations. It is possible to administer a reduced dosage of 300mg and 720mg respectively.

Template:SPCaripiprazoleLA

2025-02-20T11:08:11Z

Casper:

SwitchAntipsychotics

2025-02-20T10:45:39Z

Casper:

<div align="center">
'''Switching Antipsychotics'''

To see the consequences of a switch between antipsychotics click in the crosstable below:
the switch is made "from" (vertical) "to" (horizontal).

If you any have suggestions, please send them to medisch@boom.nl. We are looking forward to your feedback.

 During switching: don't reduce anticholinergics; consider adding oxazepam. Read: [[General considerations concerning switching antipsychotics]].

'''[[Rest AP]]''' = [[Chlorprothixene]], [[Flupentixol]], [[Fluphenazine]] [[Loxapine]], [[Pericyazine]], [[Perphenazine]],[[Promazine]], [[Trifluoperazine]], [[Ziprasidone]], [[Zuclopentixol]].

'''[[Partial agonist]]''' = [[Aripiprazole]], [[Brexpiprazole]], [[Cariprazine]].

{{Switchtable23x
| head1 = ↓ from
| head2 = to →
| titel =
| stop = Stop
| afk01 = Am | med01 = Amisulpride|
| afk02 = Cp | med02 = Clozapine|
| afk03 = Hp | med03 = Haloperidol|
| afk04 = Lu | med04 = Lurasidone|
| afk05 = Ol | med05 = Olanzapine|
| afk06 = Pp | med06 = Paliperidone|
| afk07 = Pa | med07 = Partial agonist|
| afk08 = Pf | med08 = Penfluridol|
| afk09 = Pi | med09 = Pimozide|
| afk10 = Qu | med10 = Quetiapine|
| afk11 = Rd | med11 = Risperidone|
| afk12 = Sd | med12 = Sertindole|
| afk13 = Sr | med13 = Sulpiride|
| afk14 = RA | med14 = Rest AP|
| afk15 = Da | med15 = Aripiprazole_LA |
| afk16 = Di | med16 = Flupenthixol_LA|
| afk17 = Df | med17 = Fluphenazine_LA|
| afk18 = Dh | med18 = Haloperidol_LA|
| afk19 = Do | med19 = Olanzapine_LA|
| afk20 = Dp | med20 = Paliperidone_ER|
| afk21 = Dr | med21 = Risperidone_LA|
| afk22 = Dz | med22 = Zuclopenthixol_LA|
| afk23 = Mz | med23 = Zuclopenthixol_MA |
}}
'''ER''' = ''extended release (Palmeux® + Xeplion® + Trivecta® + Byannli®)''', ''LA''' = ''long acting'', '''MA''' = ''medium acting'' 

[[category:Switchtable]]

Project:Contact

2024-03-08T13:42:31Z

Casper: /* Contactinformatie */

==Contactinformatie==

<tt>'''medisch@boom.nl'''</tt>

Template:CaveSS

2024-03-08T13:36:06Z

Casper:

<includeonly>{{#switch:{{{1}}}
| 0 =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is theoretically possible without a wash-out period, so caution is necessary.
| 1 =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is reported when a wash-out period of a week is not considered.
| 2 =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is reported when a wash-out period (of two weeks) is not considered.
| 3 =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is reported when a wash-out period (of three weeks) is not considered.
| 4 =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is reported when a wash-out period (of four weeks) is not considered.
| no =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] should not be possible, so no extra caution is necessary.
| MAOI =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is reported when a wash-out period (of four weeks) is not considered. Combination with a [[wp:Monoamine oxidase inhibitor|Monoamine oxidase inhibitor]] (MAOI) will likely increase the risks of serotonine syndrome.
| #default =* Occurrence of the [[wp:Serotonin_syndrome|serotonin syndrome]] is possible without wash-out period.
}}</includeonly><noinclude>
'''CaveSS''' template - warn against occurrence of the [[wp:Serotonin_syndrome|serotonin syndrome]].
Usage:
<nowiki>{{CaveSS}}</nowiki> without parameter results in:
{{CaveSS}}

<nowiki>{{CaveSS|2}}</nowiki> results in:
{{CaveSS|2}}

<nowiki>{{CaveSS|4}}</nowiki> results in:
{{CaveSS|4}}

<nowiki>{{CaveSS|MAOI}}</nowiki> results in:
{{CaveSS|MAOI}}

<nowiki>{{CaveSS|no}}</nowiki> results in:
{{CaveSS|no}}

</noinclude>

Template:CaveSS

2024-03-08T13:25:47Z

Casper:

<includeonly>{{#switch:{{{1}}}
| 0 =* Occurrence of [[wp:Serotonin_syndrome|serotonin syndrome]] is theoretically possible without a wash-out period, so caution is necessary.
| 1 =* Occurrence of [[wp:serotonin syndrome|serotonin syndrome]] is reported when a wash-out period of a week is not considered.
| 2 =* Occurrence of [[wp:serotonin syndrome|serotonin syndrome]] is reported when a wash-out period (of two weeks) is not considered.
| 3 =* Occurrence of [[wp:serotonin syndrome|serotonin syndrome]] is reported when a wash-out period (of three weeks) is not considered.
| 4 =* Occurrence of [[wp:serotonin syndrome|serotonin syndrome]] is reported when a wash-out period (of four weeks) is not considered.
| no =* Occurrence of [[wp:serotonin syndrome|serotonin syndrome]] should not be possible, so no extra caution is necessary.
| MAOI =* Occurrence of [[wp:serotonin syndrome|serotonin syndrome]] is reported when a wash-out period (of four weeks) is not considered. Combination with a [[wp:Monoamine oxidase inhibitor|Monoamine oxidase inhibitor]] (MAOI) will likely increase the risks of serotonine syndrome.
| #default =* Occurrence of the [[wp:Serotonin_syndrome|serotonin syndrome]] is possible without wash-out period.
}}</includeonly><noinclude>
'''CaveSS''' template - warn against occurrence of the [[wp:Serotonin_syndrome|serotonin syndrome]].
Usage:
<nowiki>{{CaveSS}}</nowiki> without parameter results in:
{{CaveSS}}

<nowiki>{{CaveSS|2}}</nowiki> results in:
{{CaveSS|2}}

<nowiki>{{CaveSS|4}}</nowiki> results in:
{{CaveSS|4}}

<nowiki>{{CaveSS|MAOI}}</nowiki> results in:
{{CaveSS|MAOI}}

<nowiki>{{CaveSS|no}}</nowiki> results in:
{{CaveSS|no}}

</noinclude>

Moclobemide-hypericum

2024-03-08T11:15:30Z

Casper:

{{Drugswitch
| from = moclobemide
| to = hypericum
| stop =
{{stopMoclobemide}}
| start =
* '''Day 9:''' start hypericum in a dosage of 300 mg one to three times a day (max 900 mg/day).

| info =
{{Shortt1/2}}
}}

Project:Updates Switch Tables

2023-08-04T14:15:44Z

Casper: /* August 2023 */

=== Updates Switch Tables ===

===== August 2023 =====
* Antidepressants: Reviewed and updated switches from and to agomelatine, moclobemide and bupropion (not finished).

===== June 2023 =====
* Antidepressants: Reviewed and updated switches from TCA to SSRI and SSRI to TCA (not finished)

===== February 2023 =====
* Antidepressants: Reviewed and updated switches from SSRI to SSRI and SSRI to SNRI (not finished)
* Changed reference of literature in switch table

===== March 2022 =====
* Antipsychotics: Certain long acting to long acting switches deleted.
* Antipsychotics: oral to different antipsychotic long acting deleted.
* Antipsychotics: added penfluridol
* Antipsychotics: added paliperidone extended release formulations (Xeplion, Trivecta, Byannli)
* Antipsychotics: ziprasidone moved to rest AP
* Antipsychotics: paliperidone moved from rest AP
* Introduced Updates Switch Tables page for informing users about changes on the Switchwiki

===== October 2021 =====
* Antipsychotics: added group partial antagonists

If you any have suggestions, please send them to info@tijdstroom.nl. We are looking forward to your feedback.

Project:Updates Switch Tables

2023-08-04T14:15:20Z

Casper: /* Updates Switch Tables */

=== Updates Switch Tables ===

===== August 2023 =====
* Antidepressants: Reviewed and updated switches from and to agomelatine, moclobemide and bupropion.

===== June 2023 =====
* Antidepressants: Reviewed and updated switches from TCA to SSRI and SSRI to TCA (not finished)

===== February 2023 =====
* Antidepressants: Reviewed and updated switches from SSRI to SSRI and SSRI to SNRI (not finished)
* Changed reference of literature in switch table

===== March 2022 =====
* Antipsychotics: Certain long acting to long acting switches deleted.
* Antipsychotics: oral to different antipsychotic long acting deleted.
* Antipsychotics: added penfluridol
* Antipsychotics: added paliperidone extended release formulations (Xeplion, Trivecta, Byannli)
* Antipsychotics: ziprasidone moved to rest AP
* Antipsychotics: paliperidone moved from rest AP
* Introduced Updates Switch Tables page for informing users about changes on the Switchwiki

===== October 2021 =====
* Antipsychotics: added group partial antagonists

If you any have suggestions, please send them to info@tijdstroom.nl. We are looking forward to your feedback.

Bupropion-sertraline

2023-08-04T12:19:03Z

Casper:

{{Drugswitch
| from = bupropion
| to = sertraline
| stop =
{{StopBupropion1}}
| start =
* ''' Day 1: ''' Start sertraline with a dosage of 25 mg/day.
* ''' Day 4: ''' If necessary, gradually increase dosage
}}

Bupropion-doxepine

2023-08-04T10:32:04Z

Casper:

{{Drugswitch
| from = bupropion
| to = doxepine
| stop =
{{StopBupropion}}
| start =
* '''Day 1:''' start administration of doxepin in a low dosage of 25mg/day.
* '''Day 8:''' increase dosage of doxepin to a dosage of 75 mg/day.

| info =
* Bupropion slows the metabolism of doxepin via CYP2D6.
* {{RiskSeizureBupropionTCA}}
* {{TCAplasmalevelmonitoring}}
}}

Escitalopram-clomipramine

2023-06-30T15:52:32Z

Casper:

{{Drugswitch
| from = escitalopram
| to = clomipramine
| stop =
{{TCAdecrease25p3d}}
| start =
{{TCAincrease25p3d}}
| info =
* {{theorSS}}
{{TCAplasmalevelmonitoring}}
}}

Duloxetine-clomipramine

2023-06-30T15:45:48Z

Casper:

{{Drugswitch
| from = duloxetine
| to = clomipramine
| stop =
{{TCAdecrease25p3d}}
| start =
{{TCAincrease25p3d}}
| info =
* {{theorSS}}
{{TCAplasmalevelmonitoring}}
}}

Project:Updates Switch Tables

2023-06-30T15:23:22Z

Casper:

=== Updates Switch Tables ===

===== June 2023 =====
* Antidepressants: Reviewed and updated switches from TCA to SSRI and SSRI to TCA (not finished)

===== February 2023 =====
* Antidepressants: Reviewed and updated switches from SSRI to SSRI and SSRI to SNRI (not finished)
* Changed reference of literature in switch table

===== March 2022 =====
* Antipsychotics: Certain long acting to long acting switches deleted.
* Antipsychotics: oral to different antipsychotic long acting deleted.
* Antipsychotics: added penfluridol
* Antipsychotics: added paliperidone extended release formulations (Xeplion, Trivecta, Byannli)
* Antipsychotics: ziprasidone moved to rest AP
* Antipsychotics: paliperidone moved from rest AP
* Introduced Updates Switch Tables page for informing users about changes on the Switchwiki

===== October 2021 =====
* Antipsychotics: added group partial antagonists

If you any have suggestions, please send them to info@tijdstroom.nl. We are looking forward to your feedback.

Citalopram-imipramine

2023-06-30T13:06:47Z

Casper:

{{Drugswitch
| from = citalopram
| to = imipramine
| stop =
{{TCAdecrease25p3d}}
| start =
{{TCAincrease25p3d}}
| info =
* {{theorSS}}
{{TCAplasmalevelmonitoring}}
}}